Please assess the completion status of the following clinical trial:

Trial Title: Rituximab Plus CHOP Chemotherapy for Diffuse Large B-cell Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent obtained and signed. Age 18-60 years. ECOG performance status (PS) 0-2. Histologically confirmed CD20-positive DLBCL, any stage, bulky or nonbulky disease.~* No prior treatment for lymphoma. Willing to have documentation of HIV status. CD4 count ≥ 100 cells/µL if HIV-infected. Measurable disease by physical exam.~* Adequate bone marrow renal and hepatic function as evidenced by the following:~  * Absolute neutrophil count (ANC) ≥ 1,000/µL~ * Platelet count ≥ 100,000/µL~ * Creatinine ≤ 1.5 mg/dL~ * Total bilirubin ≤ 2 mg/dL (unless directly attributable to lymphoma)~* Able to understand and comply with protocol requirements for the entire length of the study.~* Willing to reside \<50 kilometers from Kamuzu Central Hospital (KCH) until chemotherapy completion.~* Negative urine B-HCG in women of child-bearing potential within 7 days prior to start of treatment.~* Fertile patients must use effective contraception (condom or other barrier methods, oral contraceptives, implantable contraceptives, intrauterine devices) during and for six months after completion of treatment.~Exclusion Criteria~* Pregnant or nursing. Central nervous system (CNS) involvement by lymphoma (clinically or cytologically confirmed).~* Receiving other anti-cancer or investigational therapy during study treatment, apart from those agents specified in the study protocol.~* Known cardiac disease including any of the following:~  * New York Heart Association (NYHA) Grade II or greater congestive heart failure~ * History of myocardial infarction or unstable angina within 6 months prior to Day 1~ * History of stroke or transient ischemic attack within 6 months prior to Day 1~* Second active malignancy requiring systemic therapy.~* Hepatitis B virus (HBV) surface-antigen positive unless receiving both tenofovir and lamivudine as part of antiretroviral therapy if HIV-infected.~* Other serious, ongoing, non-malignant disease or infection that would in the opinion of the site investigator compromise other protocol objectives.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- R-CHOP (Type: EXPERIMENTAL): We will enroll 40 adult patients age 18-60 years (20 HIV-infected with CD4 count ≥ 100 cells/µL, 20 HIV-uninfected) who will receive a maximum of 6-8 cycles of rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) over 18-24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).